Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus | Zendy

María J. Gutiérrez | Zendy; Noah L. Rosenberg | Zendy; Diane MacDougall | Zendy; Jeffrey C. Hanselman | Zendy; Janice R. Margulies | Zendy; Poul Strange | Zendy; Mark A. Milad | Zendy; Scott McBride | Zendy; Roger S. Newton | Zendy

Open Access

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

Author(s) -

María J. Gutiérrez,

Noah L. Rosenberg,

Diane MacDougall,

Jeffrey C. Hanselman,

Janice R. Margulies,

Poul Strange,

Mark A. Milad,

Scott McBride,

Roger S. Newton

Publication year - 2014

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.302677

Subject(s) - medicine , placebo , cholesterol , diabetes mellitus , endocrinology , glycemic , lipoprotein , high density lipoprotein , type 2 diabetes mellitus , clinical endpoint , clinical trial , gastroenterology , pathology , alternative medicine

8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (ETC-1002) is a small molecule with a unique mechanism of action shown in nonclinical studies to modulate pathways of cholesterol, fatty acid, and carbohydrate metabolism. In previous phase 2 clinical trials, once daily oral treatment with ETC-1002 significantly reduced low-density lipoprotein-cholesterol in patients with hypercholesterolemia. In this trial, the lipid-lowering efficacy of ETC-1002 was evaluated in patients with type 2 diabetes mellitus and hypercholesterolemia. Additional cardiometabolic biomarkers, including glycemic measures, were also assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research